Liver biopsy for assessment of suspected drug‐induced liver injury in metabolic dysfunction‐associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.

MLA

Palmer, Melissa, et al. “Liver Biopsy for Assessment of Suspected Drug‐induced Liver Injury in Metabolic Dysfunction‐associated Steatohepatitis Clinical Trials: Expert Consensus from the Liver Forum.” Alimentary Pharmacology & Therapeutics, vol. 59, no. 2, Jan. 2024, pp. 201–16. EBSCOhost, https://doi.org/10.1111/apt.17762.

APA

Palmer, M., Kleiner, D. E., Goodman, Z., Brunt, E., Avigan, M. I., Regev, A., Hayashi, P. H., Lewis, J. H., Mehta, R., Harrison, S. A., Siciliano, M., McWherter, C. A., Vuppalanchi, R., Behling, C., Miller, V., Chalasani, N., & Sanyal, A. J. (2024). Liver biopsy for assessment of suspected drug‐induced liver injury in metabolic dysfunction‐associated steatohepatitis clinical trials: Expert consensus from the Liver Forum. Alimentary Pharmacology & Therapeutics, 59(2), 201–216. https://doi.org/10.1111/apt.17762

Chicago

Palmer, Melissa, David E. Kleiner, Zachary Goodman, Elizabeth Brunt, Mark I. Avigan, Arie Regev, Paul H. Hayashi, et al. 2024. “Liver Biopsy for Assessment of Suspected Drug‐induced Liver Injury in Metabolic Dysfunction‐associated Steatohepatitis Clinical Trials: Expert Consensus from the Liver Forum.” Alimentary Pharmacology & Therapeutics 59 (2): 201–16. doi:10.1111/apt.17762.